then they changed it to bausch health bausch health companies, wash off some of the stink of valeant, a loathed brand. bausch & lomb on the other hand is highly trusted. plus, the bausch eye care business accounts for the bulk of the company's sale and it was always the best. now september bausch announced a settlement with activist over the ibs drug i just mentioned. under the terms of the deal, they get a license to start making the drug, but not until 2028 until then they acknowledge the validity of bausch's patent. that removed a gigantic overhang because a lot of investors were fretting about the competition eating into sales. climbing to 28 and change in early october. but then the market wide sell-off hit and bausch plunged to 21 and change to lows turns out what a buying opportunity. >> buy, buy, buy >> because the company went on to report a blowout quarter just last week. bausch posted a monster 31 cent earns beat off high unexpected revenues the company saw organic revenue growth across all the segment, eye care, gastrointestinal, dermatology. and they want a new drug that